Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 72

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 72
---
 and payment will be
made within fifteen days.

<div align='center'>15</div>

On February 13, 2024, our majority-owned Australian
subsidiary, 60P Australia Pty Ltd, and Monash University entered into the Research Services Agreement (the “Agreement”) in
which Monash University agreed to provide research services, including among other things, testing the efficacy of Tafenoquine against
candidemia, confirming suitable fungal infection dosage and determining the pharmacokinetics of Tafenoquine following intraperitoneal
drug administration (collectively, the “Services”). The commencement date of the Agreement was effective as of February 5,
2024, and the commencement of experiments was May 2024 and the anticipated completion date is on November 30, 2024. The Company agreed
to pay Monash University $90,167 AUD on April 1, 2024 and $90,167 AUD upon the completion of the Services.

On March 20, 2024, we signed a sponsored research
agreement with North Carolina State University to conduct a pilot study to evaluate the efficacy of Tafenoquine in canine babesiosis.
The research is expected to be completed by March 30, 2026. The Company will retain ownership of all data and inventions related to the
study, subject to retained right of North Carolina State University to utilize study data or research use and publications. For a six-month
period following notification by the University, the Company retains first right of refusal to negotiate a license to utilize any inventions
or data generated by the University relevant to Tafenoquine but not occurring as a direct result of performing the planned studies. The
Company agreed to pay North Carolina State University $12,000 upon contract execution, $8,000 around October 1, 2024, then
$3,869 around April 1, 2025 when work is expected to be completed.

On May 10, 2024, we entered into a sponsored research
agreement with North Carolina State University to conduct a study to evaluate the incidence of Babesia infection amongst archived blood
samples from patients with chronic fatigue and neurocognitive problems. The research will be completed by May 31, 2025. The Company retains
the right to use all study data, joint and University-owned inventions for non-commercial purposes and first right of refusal to negotiate
a royalty bearing license for commercial purposes for any university own intellectual property or ownership interest in jointly-owned